About Novoprotein
Founded in 2005, Novoprotein specialises in recombinant protein technologies and develops research reagents, enzymes and biologics that support drug discovery, vaccine development, cell therapy and molecular diagnostics. The company combines protein engineering, expression and quality control capabilities to produce recombinant proteins, cytokines, antibodies and molecular biology reagents for life science research and biopharmaceutical development. Its technology platforms support applications across immunology, oncology, stem cell biology, gene editing, infectious disease research and translational medicine, enabling researchers to study biological pathways, develop therapeutic candidates and optimise advanced therapeutic workflows.
Novoprotein offers a broad portfolio that includes GMP-grade cytokines, target proteins, recombinant antibodies, biosimilar reference antibodies, CRISPR/Cas reagents, BenzoNuclease®, PCR and qPCR enzymes, next-generation sequencing reagents, and products for mRNA vaccine and drug development. The company also provides enzymes for plasmid linearisation, in vitro transcription, mRNA capping and tailing, purification and quality control, supporting the complete mRNA production workflow. Its reagents and diagnostic raw materials are used in molecular diagnostics, immunoassay development, gene and cell therapy research, and vaccine manufacturing.
Europa Biosite subsidiaries distribute Novoprotein products in Austria, Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland, the United Kingdom and the United States of America.